- Home
- ATCX vs HIND Comparison
ATCX vs HIND Comparison
Compare ATCX & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ATCX | HIND |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Brazil | United States |
| Employees | N/A | 2 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8M | 15.2M |
| IPO Year | 2016 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ATCX | HIND |
|---|---|---|
| Price | $3.12 | $2.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $13.75 | ★ $15.00 |
| AVG Volume (30 Days) | 6.5K | ★ 14.5K |
| Earning Date | 03-16-2023 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 64.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $319,714.00 |
| Revenue This Year | $827,667.00 | N/A |
| Revenue Next Year | $166.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.43 |
| 52 Week Low | $2.57 | $1.75 |
| 52 Week High | $14.01 | $6.56 |
Technical Indicators
Market Signals| Indicator | ATCX | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 46.91 |
| Support Level | $2.88 | $1.99 |
| Resistance Level | $3.26 | $2.31 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 38.89 | 43.06 |
Price Performance
Historical ComparisonAbout ATCX Atlas Critical Minerals Corporation Common Stock
Atlas Critical Minerals Corp is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.
About HIND Vyome Holdings Inc.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.